---
schema_version: "secwatch.filing_event.v1"
accession: "0001323885-22-000003"
form_type: "8-K"
ticker: "ATRC"
cik: "0001323885"
company_name: "AtriCure, Inc."
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:15:49.205223+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AtriCure reports preliminary Q4 revenue $73.2M (+27% YoY), guides FY2022 $315-330M

## Summary
- Q4 2021 revenue ~$73.2M (+27% YoY); U.S. $61.2M (+29%), Intl $12.0M (+16% as reported).
- Full year 2021 revenue $274.3M (+33% YoY); adj. EBITDA loss ~$10M, adj. loss per share ~$1.20.
- Management guides FY2022 revenue $315-330M (15-20% growth over 2021), subject to pandemic uncertainty.
- Preliminary, unaudited results – final audited results with GAAP reconciliation to follow in later release.

## SEC filing metadata
- accession: 0001323885-22-000003
- form_type: 8-K
- ticker: ATRC
- cik: 0001323885
- company_name: AtriCure, Inc.
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/0001323885-22-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1323885/000132388522000003/atrc-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001323885-22-000003
- JSON: https://secwatch.observer/filing/0001323885-22-000003.json
- Plain text: https://secwatch.observer/filing/0001323885-22-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.